Gelesis Holdings Price to Free Cash Flow Ratio 2021-2022 | GLS

Historical price to free cash flow ratio values for Gelesis Holdings (GLS) since 2021. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Gelesis Holdings Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-08-12 1.63 0.83
2022-03-31 4.53 $1.96 2.31
2021-12-31 9.96 $-0.06 0.00
2021-09-30 9.92 $-0.02 0.00
2021-06-30 9.79 $0.01 789.52
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.117B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.991B 9.65
GSK (GSK) United Kingdom $72.663B 8.73
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.304B 18.93
Biohaven Pharmaceutical Holding (BHVN) United States $10.553B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.041B 0.00
Arcus Biosciences (RCUS) United States $1.868B 36.45
Myovant Sciences (MYOV) United Kingdom $1.698B 0.00
Emergent Biosolutions (EBS) United States $1.490B 8.64
Zymeworks (ZYME) Canada $0.404B 0.00
Enzo Biochem (ENZ) United States $0.131B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00